Mar 16, 2023 4:04 pm EDT CymaBay Reports Fourth Quarter and Year Ended December 31, 2022 Financial Results and Provides Corporate Update
Mar 09, 2023 4:05 pm EST CymaBay Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
Mar 01, 2023 8:00 am EST CymaBay Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
Feb 06, 2023 8:00 am EST CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference
Jan 30, 2023 8:00 am EST CymaBay Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jan 24, 2023 7:00 am EST CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Jan 23, 2023 4:11 pm EST CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Jan 08, 2023 12:00 pm EST CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis
Nov 14, 2022 4:06 pm EST CymaBay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial Results and Provides Corporate Update
Nov 07, 2022 4:05 pm EST CymaBay Therapeutics to Report Third Quarter of 2022 Financial Results on Monday, November 14, 2022